Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
223 2 |
Ultima descărcare din IBN: 2023-08-23 18:06 |
Căutarea după subiecte similare conform CZU |
616.831-009.7:616.9:578.834.1 (1) |
Neurologie. Neuropatologie. Sistem nervos (971) |
Boli transmisibile. Boli infecţionase şi contagioase, stări febrile (585) |
Virologie (442) |
SM ISO690:2012 NACU, Gabriela, GROSU, Oxana, CORCEA, Galina, ODOBESCU, Stela. Persistent post-COVID 19 headache: results of a national survey. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 291. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.831-009.7:616.9:578.834.1 | ||||||
Pag. 291-291 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Covid 19 infection is a multisystemic disease, with severe nervous system involvement. Studies have shown that approximately 34% to 75% of patients experience acute Covid 19 headache, and in 1/3 cases it can persist for an indefinite time. Objective of the study. Evaluation of post-Covid 19 headache’s persistence in patients with acute headache history during the acute period of Covid 19 infection. Material and Methods. This study is a survey. People, previously involved in the national survey of Headache in the context of the COVID 19 pandemic, were asked to complete online a structured questionnaire. These patients had been tested serologically Covid 19 positive for the first time- more than 9 months ago. Results. From 140 people previously involved in the study „Headache in the context of COVID-19 pandemic - the results of a national survey”, 89 patients completed the questionnaire about the persistence of post-Covid 19 headache, from which 30 people (33.7%) mentioned the persistence of headache after recovery, of which 96.7% (29p) - women with mean age 41.96 ± 10.84. Mostly, we observed a moderate-severe intensity of the headache, which was localized in 33.3% (10p) in frontal region, with a predominantly oppressive character in 56.7% cases. In 60% cases, patients have experienced 1-2 times/ week headache using in 5.3 ± 4.74 days/month (min 0.0; max 15.0) drug treatment. Conclusion. The headache is a disabling symptom of Covid 19 infection that persists even after recovery; it is clinically manifested by severe, moderatesevere pain affecting young women, a clinical feature highlighted in other previous studies. |
||||||
Cuvinte-cheie headache, post Covid-19, chronic, cefalee, post-Covid-19, cronicizare |
||||||
|